MDCX · Medicus Pharma Ltd.
Medicus Pharma Ltd (MDCX)
What's happening
- MDCX is down 4.90% today, trading at $2.72. — Live quote
- It's trading within 3% of its 52-week low ($2.55). (Finnhub fundamentals)
- Volume today (215) is well below its 3-month average of 85,460. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-10.50 actual vs. $-6.50 estimated (-61.5%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.24B | $661.5M | $267.5M | $269.3M | $271.9M |
| P/E | -25.92 | -16.03 | -7.75 | — | — |
| Price/Book | -702.02 | 498.87 | -293.91 | — | — |
| ROE | 2708.68% | -3111.21% | 3789.91% | — | — |
| ROA | -176.17% | -555.50% | -345.70% | — | — |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-16; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -97.8%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on MDCX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$11.5M | -$8.6M | -$15 | -$6.0M | -$5.1M | -$2.3M | -$3.6M | -$1.7M |
| Net income | -$11.6M | -$9.0M | -$20.9M | -$6.2M | -$5.1M | -$2.3M | — | -$1.7M |
| EPS (diluted) | $-0.21 | $-0.31 | $-1.12 | $-0.43 | $-0.42 | $-0.24 | $-0.44 | $-0.21 |
| EPS (basic) | $-0.21 | $-0.31 | $-1.12 | $-0.43 | $-0.42 | $-0.24 | $-0.44 | $-0.21 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Dec '23 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $27.1M | $7.4M | $10.1M | $10.0M | $11.9M | $5.7M | $5.6M | $1.9M |
| Total liabilities | $28.8M | $6.0M | $10.0M | $10.8M | $8.7M | $3.5M | $2.5M | $781.6K |
| Stockholders' equity | -$1.8M | $1.3M | -$67.6K | -$910.1K | — | — | $3.1M | — |
| Total current assets | $17.0M | $7.3M | $9.9M | $9.8M | $11.0M | $5.1M | $5.4M | $1.9M |
| Total current liabilities | $10.8M | $6.0M | $9.9M | $10.7M | $8.5M | $3.3M | $2.3M | $781.6K |
| Cash & equivalents | $15.2M | $6.4M | $8.7M | $8.7M | $9.7M | $4.0M | $4.2M | $1.7M |
| Accounts payable | $6.7M | $2.3M | $3.4M | $2.0M | $1.8M | $2.0M | $1.3M | $210.8K |
| Common stock & paid-in capital | $74.3M | $67.1M | $57.1M | $4 | $37.8M | $32.9M | $30.5M | $18.8M |
| Retained earnings | -$85.0M | -$73.4M | -$64.3M | -$5 | -$40.2M | -$34.0M | -$28.9M | -$17.7M |
| Accumulated other comprehensive income (loss) | $61.1K | -$190.5K | $10.9K | $10.7K | — | — | $0 | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.0M | -$9.0M | -$6.6M | -$6.8M | -$5.5M | -$3.9M | -$3.2M | -$3.1M |
| Investing cash flow | — | — | $0 | -$4.6M | — | — | $0 | $0 |
| Financing cash flow | $25.5M | $6.8M | $6.7M | $10.4M | $11.2M | $3.8M | $2.0M | $0 |
| Share-based compensation | $1.4M | $599.3K | $429.7K | $852.8K | $117.4K | $112.3K | $91.7K | $0 |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts payable | — | — | — | — | -$251.0K | $655.6K | $153.5K | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Operating income | -$34.4M | -$11.2M | -$4.7M |
| Net income | -$47.3M | -$11.2M | -$5.3M |
| EPS (diluted) | $-2.74 | $-1.16 | $-1.53 |
| EPS (basic) | $-2.74 | $-1.16 | $-1.53 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Total assets | $10.1M | $5.6M | $1.9M |
| Total liabilities | $10.0M | $2.5M | $781.6K |
| Stockholders' equity | -$67.6K | $3.1M | — |
| Total current assets | $9.9M | $5.4M | $1.9M |
| Total current liabilities | $9.9M | $2.3M | $781.6K |
| Cash & equivalents | $8.7M | $4.2M | $1.7M |
| Accounts payable | $3.4M | $1.3M | $210.8K |
| Common stock & paid-in capital | $57.1M | $30.5M | $18.8M |
| Retained earnings | -$64.3M | -$28.9M | -$17.7M |
| Accumulated other comprehensive income (loss) | $10.9K | $0 | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Operating cash flow | -$22.8M | -$10.2M | -$4.2M |
| Investing cash flow | -$4.6M | $0 | — |
| Financing cash flow | $31.9M | $12.7M | $5.6M |
| Share-based compensation | $1.5M | $713.1K | $98.6K |
| Deferred income taxes | $0 | $0 | — |
| Change in accounts payable | — | $808.7K | $79.1K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding MDCX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-09-04 to 2026-09-04
Recent transactions
- Most recent: Smith Andrew Alasdair (Chief Operating Officer) — Grant / award of 735,294 shares on 2026-09-04.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Smith Andrew Alasdair | Chief Operating Officer | Grant / award | 2026-09-04 | 735,294 |
| Mehmud Faisal | Chief Medical Officer | Grant / award | 2026-09-04 | 1,470,588 |
| Brennan Edward J. | Chief Scientific Officer | Grant / award | 2026-09-04 | 588,235 |
| Bonner Carolyn F. | President and CFO | Grant / award | 2026-09-04 | 1,470,588 |
| Bokhari Raza | Chief Executive Officer | Grant / award | 2026-09-04 | 2,941,176 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-04 | Smith Andrew Alasdair | Chief Operating Officer | Grant / award | 735,294 | $0.17 |
| 2026-09-04 | Mehmud Faisal | Chief Medical Officer | Grant / award | 1,470,588 | $0.17 |
| 2026-09-04 | Brennan Edward J. | Chief Scientific Officer | Grant / award | 588,235 | $0.17 |
| 2026-09-04 | Bonner Carolyn F. | President and CFO | Grant / award | 1,470,588 | $0.17 |
| 2026-09-04 | Bokhari Raza | Chief Executive Officer | Grant / award | 2,941,176 | $0.17 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:48 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-16 | 8-K | 2026-10-12 | View on SEC.gov → |
| 2026-10-07 | 8-K | 2026-10-07 | View on SEC.gov → |
| 2026-09-14 | 8-K | 2026-09-11 | View on SEC.gov → |
| 2026-09-11 | 8-K | 2026-09-04 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-03 | 8-K | 2026-09-02 | View on SEC.gov → |
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-06-04 | 8-K | 2026-06-03 | View on SEC.gov → |
Recent news
Headlines about MDCX (Medicus Pharma Ltd.). Links open the publisher — we don’t host full articles.
-
Form PRE 14A MEDICUS PHARMA LTD. For: 19 October By Investing.com
Investing.com South Africa · 2026-10-20 -
MDCX PRE 14A & SEC Filings
Yahoo Finance · 2026-10-19 -
Maxim Group Maintains Medicus Pharma(MDCX.US) With Buy Rating, Cuts Target Price to $15
富途牛牛 · 2026-10-19 -
409,411 directly owned shares are only part of an amended Medicus Pharma (MDCX) stake report.
Stock Titan · 2026-10-16 -
Medicus Pharma Warrant (MDCXW) Jumps 66.67% to $0.20 as Buyers Probe Upper Range - Equity Put Call
https://www.dars.gov.et/ · 2026-10-16 -
MDCX 8-K & SEC Filings
Yahoo Finance · 2026-10-16 -
Friday's after hours session: top gainers and losers
ChartMill · 2026-10-09 -
These stocks are moving in today's pre-market session
ChartMill · 2026-10-09
No headlines in this category right now — try “All”.